Core Insights - Editas Medicine, Inc. has announced its three-year strategic priorities and key milestones for 2025, focusing on in vivo gene editing for serious diseases [1][4] - The company aims to establish itself as a leader in in vivo programmable gene editing, supported by recent scientific breakthroughs and preclinical data [2][4] In Vivo Gene Editing Developments - New in vivo preclinical proof of concept data has been achieved in non-human primates for editing hematopoietic stem cells (HSCs) and liver cells, demonstrating the potential of the gene upregulation strategy [3][4] - The company has successfully demonstrated high efficiency in delivering gene editing to extrahepatic cell types using its proprietary lipid nanoparticle (LNP) targeting platform in humanized mice [3][5] 2025 Key Milestones - Anticipated milestones for 2025 include declaring two in vivo development candidates, presenting further in vivo HSC data, and establishing an additional target cell type/tissue [4][12] - The company plans to submit at least one investigational new drug (IND) application by mid-2026 and commence late-stage trials for at least one asset by the second half of 2027 [12] Financial Position - As of December 31, 2024, the company reported approximately $270 million in cash, cash equivalents, and marketable securities, with a cash runway extending into Q2 2027 [8] Upcoming Presentation - The company will present its new in vivo preclinical data and strategic priorities at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [9]

Company Overview - Editas Medicine, Inc. is a leading gene editing company focused on utilizing CRISPR/Cas12a and CRISPR/Cas9 genome editing systems to develop in vivo medicines for serious diseases globally [3]. Upcoming Event - The President and CEO of Editas Medicine, Gilmore O'Neill, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA [1]. Presentation Access - A live webcast of the presentation will be available on the "Investors" section of the Editas Medicine website, with an archived replay accessible for approximately 30 days post-presentation [2].

Core Viewpoint - Editas Medicine announced the termination of its lead gene editing therapy, reni-cel, leading to a 23.8% drop in shares due to a lack of commercial partnership and a significant cash crunch [1][2][3] Company Developments - Editas plans to collaborate with clinical study sites and regulators to determine the future for patients in the RUBY and EdiTHAL studies, which have been abandoned [2] - The company will focus on in vivo pipeline development, aiming for human proof of concept in about two years, while implementing cost-saving measures and reducing its workforce by approximately 65% over the next six months to extend its cash runway into Q2 2027 [3][4] - Editas has demonstrated in vivo preclinical proof of concept for editing hematopoietic stem and progenitor cells, achieving around 40% editing of the HBG1/2 promoter site using its proprietary targeted lipid nanoparticle (tLNP) system [6][7][8] Clinical and Market Outlook - The in vivo candidate for SCD and TDT has not yet entered clinical-stage development, indicating a lengthy timeline before commercialization [4] - Editas believes it has a clear path to develop a potentially first- and best-in-class in vivo gene-edited medicine for SCD and TDT, which could be more beneficial than the ex-vivo candidate, reni-cel [10] - The company expects to share pre-clinical data and development timelines in Q1 2025 [11] Stock Performance - Over the past three months, Editas shares have decreased by 62.7%, compared to an 11.1% decline in the industry [5]

Core Insights - Editas Medicine is transitioning to focus exclusively on in vivo CRISPR-edited medicines, driven by recent scientific advancements that have accelerated timelines for viability in this area [2][3] - The company has achieved significant pre-clinical proof of concept in multiple tissues, including a ~40% editing of the HBG1/2 promoter site in hematopoietic stem cells (HSCs) and high efficiency editing in the liver of non-human primates [3][4] - Editas plans to extend its cash runway into Q2 2027 through cost-saving measures, including a reduction of approximately 65% of its workforce [6][10] Scientific Progress - The company has successfully induced HbF expression in human red blood cells, with an average of 20% HbF expressing cells observed one month post-treatment in mice [3] - The proprietary targeted lipid nanoparticle (tLNP) formulation was utilized for effective delivery of gene editing machinery to HSCs [3] - High efficiency editing in the liver was achieved in collaboration with Genevant, with further data expected to be shared in Q1 2025 [4] Strategic Changes - Editas is discontinuing the development of reni-cel due to the inability to secure a commercial partner, and will focus on the RUBY and EdiTHAL trials for sickle cell disease and beta thalassemia [1][8] - The company is implementing a significant workforce reduction, which will include departures from the management team [6][7] - The transition to a fully in vivo company is aimed at expanding therapeutic possibilities and positioning Editas as a leader in the CRISPR gene editing field [2][5]

It has been about a month since the last earnings report for Editas Medicine (EDIT) . Shares have lost about 36.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Editas Q3 Loss Narrower Than Expected, Revenue ...

Editas Medicine, Inc. (NASDAQ:EDIT) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Erick Lucera - Executive Vice President and Chief Financial Officer Cristi Barnett - Senior Vice President, Corporate Communications and Investor Relations Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Okay, welcome everyone. This is Evercore’s Healthcare Conference. I'm Liisa Bayko, one of this mid-cap analysts here at Evercore, and I've been covering Editas a ...

BofA Securities downgraded Editas Medicine Inc EDIT, citing few value-driving catalysts in the near term. In its third-quarter earnings release, Editas Medicine said it engaged an investment bank to lead the process of partnering or out-licensing reni-cel (renizgamglogene autogedtemcel, previously EDIT-301). The company is developing reni-cel for sickle cell disease and transfusion-dependent Beta Thalassemia. The company is on track to share additional clinical and patient-reported outcomes data from 28 pat ...

Editas Medicine, Inc. (NASDAQ:EDIT) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera - Chief Financial Officer Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha All right. Thanks, everyone, for joining us for the next half hour. My name is Dae Gon Ha, one of the biotech analysts at Stifel. So with me for the next half hour, we've got Editas Medicine. So from Editas, we have Erick Lucera, Chief Financial Officer and Christine [indiscernible] VP of IR. ...

Editas Medicine (EDIT) incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported a loss of 55 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $0.1 million in the reported quarter, down from $5.3 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $7 million. Th ...

Editas Medicine (EDIT) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.32%. A quarter ago, it was expected that this genome editing company would post a loss of $0.69 per share when it actually produced a loss of $0.82, delivering a surprise of -18.84%.Over the last four quarters, the compa ...